Search results for "MIP"

showing 10 items of 623 documents

Additivity of the Equationally-Defined Commutator and Relatively Congruence-Distributive Subquasivarieties

2015

Pure mathematicsDistributive propertylawAdditive functionSemiprimeCongruence (manifolds)Commutator (electric)Mathematicslaw.invention
researchProduct

Biosensors for the determination of SARS-CoV-2 virus and diagnosis of COVID-19 infection

2022

Monitoring and tracking infection is required in order to reduce the spread of the coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To achieve this goal, the development and deployment of quick, accurate, and sensitive diagnostic methods are necessary. The determination of the SARS-CoV-2 virus is performed by biosensing devices, which vary according to detection methods and the biomarkers which are inducing/providing an analytical signal. RNA hybridisation, antigen-antibody affinity interaction, and a variety of other biological reactions are commonly used to generate analytical signals that can be precisely detected using electro…

QH301-705.5immune complexSARS-CoV-2 virusBiosensing TechniquesReviewCatalysisInorganic Chemistryelectrochemical immunosensorsCOVID-19 TestingHumansSerologic TestsPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopySARS-CoV-2bioelectrochemistryOrganic ChemistryCOVID-19General MedicineRNA analysisbiosensorsimmobilisation of biomoleculesNanostructuresComputer Science ApplicationsChemistryMolecular Diagnostic Techniquesmolecularly imprinted polymers (MIPs)antigen-antibody interactionCOVID-19 ; SARS-CoV-2 virus ; biosensors ; electrochemical immunosensors ; bioelectrochemistry ; RNA analysis ; antigen-antibody interaction ; immune complex ; immobilisation of biomolecules ; molecularly imprinted polymers (MIPs)
researchProduct

Lipid-containing semipermeable membrane devices (SPMDs) as concentrators of toxic chemicals in the lower Fraser River, Vancouver, British Columbia.

1998

Abstract Semipermeable membrane devices (SPMDs) were deployed in the water column and in the sediments of the Lower Fraser River (B.C., Canada) to compare the levels and the congener profiles of polychlorinated dibenzo- p -dioxins (PCDDs), dibenzofurans (PCDFs) and non- ortho -chlorinated biphenyls (N-o,o′-PCBs) against those sampled by an Infiltrex resin column water sampler. Also the relationship between what was present in the ecosystem as sampled by SPMDs and what was accumulated in the tissue of resident benthic-feeding fish was explored. Only the lipid portion of the SPMDs was prepared for analysis, due to some technical difficulties in cleaning the polyethene tubing. The calculated w…

Quality ControlEnvironmental EngineeringHealth Toxicology and MutagenesisGas Chromatography-Mass Spectrometrychemistry.chemical_compoundWater columnEnvironmental ChemistryAnimalsSemipermeable membraneWater pollutionBenzofuransBritish ColumbiaChemistryPublic Health Environmental and Occupational HealthFishesMembranes ArtificialGeneral MedicineGeneral ChemistryMultiple sourcePollutionLipidsPolychlorinated BiphenylsChlorinated BiphenylsPentachlorophenolCongenerSemipermeable membrane devicesEnvironmental chemistryWater Pollutants ChemicalChemosphere
researchProduct

Semipermeable membrane to retain platinum atoms in the electrodeposition process of alpha spectrometry sources

1998

Abstract In earlier work alpha sources electrodeposited on stainless steel backings were analyzed by X-ray fluorescence (XRF) and Rutherford backscattering spectrometry (RBS) finding that during the electrodeposition process large quantities of platinum from the anode were deposited on the cathode surface jointly with the actinides. In the present work, a method to retain platinum atoms using an electrodeposition cell with a semipermeable membrane located between anode and cathode is proposed and tested. The XRF and RBS of alpha sources electrodeposited using this method show that there is less platinum on the stainless steel backing, thereby improving the quality of sources to be measured …

RadiationMaterials scienceAlpha spectrometryAnalytical chemistrychemistry.chemical_elementActinideRutherford backscattering spectrometryCathodelaw.inventionAnodechemistrylawScientific methodSemipermeable membranePlatinumApplied Radiation and Isotopes
researchProduct

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

2011

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS Following median (interquartile range) 71 (63–86) days drug withdrawal, overall glycemic status remained modestly improved in t…

RamiprilAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPlaceboRosiglitazone03 medical and health sciencesDrug withdrawal0302 clinical medicineRamiprilInterquartile rangeInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsGlycemicOriginal ResearchAdvanced and Specialized Nursingbusiness.industryIncidence (epidemiology)IncidenceClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.disease3. Good healthSurgerySubstance Withdrawal SyndromeTreatment OutcomeDiabetes Mellitus Type 2FemaleThiazolidinedionesRosiglitazonebusinessmedicine.drugFollow-Up StudiesDiabetes Care
researchProduct

Strict blood-pressure control and progression of renal failure in children

2009

PubMedID: 19846849 BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting- enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m2 of body-surface area) received ramipril at a dose of 6 mg per square meter of bodysurface area per day…

RamiprilMaleMean arterial pressuremedicine.medical_specialtyAdolescentUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureKaplan-Meier EstimateRamiprilmedicineClinical endpointHumansRenal Insufficiency ChronicChildDEPARTMENTSAntihypertensive AgentsProteinuriabusiness.industryHazard ratioGeneral MedicineBlood Pressure Monitoring Ambulatorymedicine.diseaseSurgeryProteinuriaBlood pressureChild PreschoolCreatinineHypertensionDisease ProgressionKidney Failure ChronicDrug Therapy CombinationFemalemedicine.symptombusinessKidney diseasemedicine.drugGlomerular Filtration Rate
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpo…

2009

Hypertension guidelines advise aggressive blood pressure (BP) lowering in patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Twenty-five thousand five hundred and eighty-eight patients with atherosclerotic disease or diabetes with organ damage, tolerant to angiotensin-converting enzyme inhibitors, were randomized to ramipril, telmisartan or both. We related the primary composite outcome and its components to: baseline SBP; SBP changes from baseline to…

RamiprilMalemedicine.medical_specialtyPhysiologyAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineInternal MedicinemedicineHumansTelmisartanRisk factorAntihypertensive AgentsAgedVascular diseasebusiness.industryMiddle Agedmedicine.diseasePrognosisAngiotensin IISurgeryClinical trialBlood pressureTreatment OutcomeHypertensionCardiologyBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeco…

2013

Objective: The Survival of Myocardial Infarction Long-term Evaluation 4 Study (SMILE-4) showed the superiority of Zofenopril (Z) associated with Acetylsalicylic Acid (ASA) as respect to Ramipril (R) plus ASA in reducing the occurrence of major cardiovascular events, in patients with left ventricular dysfunction (LVD) following Acute Myocardial Infarction (AMI). The objective of this retrospective analysis was the evaluation of cost-effectiveness of Z compared to R. Methods: 771 patients with LVD and AMI were randomized, double-blind to Z 60 mg/day (n=389) or R 10 mg/day (n=382) plus ASA 100 mg/day and followed-up for 1 year. The primary study end-point was 1-year combined occurrence of deat…

RamiprilPediatricsmedicine.medical_specialtyeducation.field_of_studybusiness.industryCost effectivenessSurrogate endpointPopulationmedicine.diseaseConfidence intervalZofenoprilchemistry.chemical_compoundchemistryInternal medicinemedicineCardiologyNumber needed to treatMyocardial infarctionCardiology and Cardiovascular Medicinebusinesseducationhealth care economics and organizationsmedicine.drugEuropean Heart Journal
researchProduct

Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor bl…

2006

BACKGROUND.: In this study the effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on blood pressure and left ventricular mass (LVM) and function, have been evaluated in hypertensives. METHODS.: 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM, LVM/h(2.7) and other echocardiographic measurements, BUN, creatinine and clearance and potassium were determined …

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyLeft ventricular geometry and functionAngiotensin II receptor blockersLeft ventricular hypertrophyEssential hypertensionArticlechemistry.chemical_compoundInternal medicinemedicineAce-inhibitors Angiotensin II receptor blockers Left ventricular geometry and functioncardiovascular diseasesAce-inhibitorsCreatininebusiness.industrymedicine.diseaseAngiotensin IILosartanBlood pressurechemistrylcsh:RC666-701ACE inhibitorCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugHeart International
researchProduct